About Amryt PharmaAmryt Pharma is a specialty pharmaceutical company focused on the developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.
CEO: Joe Wiley
CFO/COO: Rory Nealon
FOLLOW AMRYT PHARMA:
Tweets by Amryt Pharma
48 articles with Amryt Pharma
These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.
Amryt, a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases, will announce a trading update for the nine-months ended 30 September 2019 on Tuesday, 5 November 2019.
Amryt, a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases, announces interim results for the six months ended 30 June 2019.
IDMC recommends study can enrol children and infants aged from 21 days to 4 years
Amryt, a revenue generating orphan drug company focused on acquiring, developing & commercialising products that help to improve the lives of patients where there is a high unmet medical need, today announces an update on its pivotal Phase III EASE trial for AP101 as a potential treatment for Epidermolysis Bullosa (“EB”).
Amryt’s lead commercial product now available in all five of the EU’s largest markets
Amry today announces that the US Food and Drug Administration (“FDA”) has granted Investigational New Drug (“IND”) clearance for AP101.
Treatment Of Rare Skin Disorder By Amryt Pharma Gets EUR 20 Million Backing From European Investment Bank’s First Ever Pharma Loan In Ireland